These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 28634704)

  • 1. Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?
    Piantanida E; Bartalena L
    J Endocrinol Invest; 2017 Aug; 40(8):885-887. PubMed ID: 28634704
    [No Abstract]   [Full Text] [Related]  

  • 2. Current and Emerging Treatment Strategies for Graves' Orbitopathy.
    Genere N; Stan MN
    Drugs; 2019 Feb; 79(2):109-124. PubMed ID: 30659423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Teprotumumab for Graves' orbitopathy and ototoxicity: moving problems from eyes to ears?
    Bartalena L; Marinò M; Marcocci C; Tanda ML
    J Endocrinol Invest; 2022 Jul; 45(7):1455-1457. PubMed ID: 35403994
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy.
    Wiersinga WM
    Lancet Diabetes Endocrinol; 2017 Feb; 5(2):134-142. PubMed ID: 27346786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of moderate-to-severe and active Graves' orbitopathy: a step forward from the OPTIC study.
    Tanda ML; Gallo D; Ippolito S; Bartalena L; Piantanida E
    J Endocrinol Invest; 2020 Oct; 43(10):1523-1525. PubMed ID: 32306294
    [No Abstract]   [Full Text] [Related]  

  • 6. Teprotumumab: First Approval.
    Markham A
    Drugs; 2020 Apr; 80(5):509-512. PubMed ID: 32157641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reply to Letter to the Editor by Dr. Terry J. Smith regarding teprotumumab and ototoxicity.
    Bartalena L; Marcocci C; Tanda ML; Marinò M
    J Endocrinol Invest; 2022 Aug; 45(8):1603-1604. PubMed ID: 35633498
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of moderate to severe orbitopathy: Current modalities and perspectives.
    Bouzehouane N; Borson-Chazot F; Abeillon J; Caron P
    Ann Endocrinol (Paris); 2021 Apr; 82(2):92-98. PubMed ID: 33676921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teprotumumab in Thyroid-Associated Ophthalmopathy: Rationale for Therapeutic Insulin-Like Growth Factor-I Receptor Inhibition.
    Smith TJ
    J Neuroophthalmol; 2020 Mar; 40(1):74-83. PubMed ID: 32040069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid-associated ophthalmopathy: Emergence of teprotumumab as a promising medical therapy.
    Smith TJ
    Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101383. PubMed ID: 32088116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum selenium status in Graves' disease with and without orbitopathy: a case-control study.
    Khong JJ; Goldstein RF; Sanders KM; Schneider H; Pope J; Burdon KP; Craig JE; Ebeling PR
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):905-10. PubMed ID: 24372054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel treatment modalities for Graves' orbitopathy.
    Bartalena L; Lai A; Sassi L; Lombardi V; Dalle Mule I; Gandolfo M; Liparulo L; Azzolini C; Piantanida E; Tanda ML
    Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():210-6. PubMed ID: 20467365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Novel treatment opportunities in Graves' orbitopathy].
    Erdei A; Gazdag A; Bodor M; Berta E; Katkó M; Ujhelyi B; Steiber Z; Győry F; Urbancsek H; Barna S; Galuska L; Nagy VE
    Orv Hetil; 2014 Aug; 155(33):1295-300. PubMed ID: 25109914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum concentrations of HGF and IL-8 in patients with active Graves' orbitopathy before and after methylprednisolone therapy.
    Nowak M; Siemińska L; Karpe J; Marek B; Kos-Kudła B; Kajdaniuk D
    J Endocrinol Invest; 2016 Jan; 39(1):63-72. PubMed ID: 26062519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Teprotumumab for Active Thyroid Eye Disease.
    Kim S; Patzek S
    N Engl J Med; 2020 May; 382(20):1958-1959. PubMed ID: 32402170
    [No Abstract]   [Full Text] [Related]  

  • 17. Rapid Development of Graves' Ophthalmopathy After Treatment With Ipilimumab and Recurrence With Pembrolizumab in a Patient With Previously Treated Graves' Disease.
    Rhea L; Yoon JW; Jang S
    J Oncol Pract; 2018 Dec; 14(12):747-749. PubMed ID: 30537449
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.
    Bartalena L; Tanda ML
    J Endocrinol Invest; 2006 Dec; 29(11):1012-6. PubMed ID: 17259800
    [No Abstract]   [Full Text] [Related]  

  • 19. CD28/CTLA-4/ICOS haplotypes confers susceptibility to Graves' disease and modulates clinical phenotype of disease.
    Pawlak-Adamska E; Frydecka I; Bolanowski M; Tomkiewicz A; Jonkisz A; Karabon L; Partyka A; Nowak O; Szalinski M; Daroszewski J
    Endocrine; 2017 Jan; 55(1):186-199. PubMed ID: 27638540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed graves' hyperthyroidism seen at a single center.
    Tanda ML; Piantanida E; Liparulo L; Veronesi G; Lai A; Sassi L; Pariani N; Gallo D; Azzolini C; Ferrario M; Bartalena L
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1443-9. PubMed ID: 23408569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.